Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

A 22-year-old Omaha woman has been attending a long COVID program at Madonna Rehabilitation for months after contracting the virus multiple times while working as a certified nursing assistant.

Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19,” published in the February 2025 ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

Non-active site mutations such as L50F are crucial for restoring the viral fitness of SARS-CoV-2 main protease. Here, the authors use full-length Mpro protein as substrate and demonstrate that ...

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox.

There are two instances where people should consider testing. The first is if they would qualify for antiviral treatment for Covid-19 or influenza. These are individuals at high risk for ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...